Cargando…
The Schistosomiasis Consortium for Operational Research and Evaluation 2008–2020: Approaches, Experiences, Lessons, and Recommendations
For the past 10 years, the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE), funded by the Bill & Melinda Gates Foundation, has been supporting operational research to provide a stronger evidence base for controlling and moving toward elimination of schistosomiasis. The...
Autores principales: | Binder, Sue, Campbell, Carl H., Andros, Tamara S., Castleman, Jennifer D., Kittur, Nupur, King, Charles H., Colley, Daniel G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Tropical Medicine and Hygiene
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351309/ https://www.ncbi.nlm.nih.gov/pubmed/32400350 http://dx.doi.org/10.4269/ajtmh.19-0786 |
Ejemplares similares
-
Contributions of the Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) to Schistosomiasis Control and Elimination: Key Findings and Messages for Future Goals, Thresholds, and Operational Research
por: Colley, Daniel G., et al.
Publicado: (2020) -
Environmental Predictors of Schistosomiasis Persistent Hotspots following Mass Treatment with Praziquantel
por: Walker, Joseph W., et al.
Publicado: (2020) -
Challenges in Protocol Development and Interpretation of the Schistosomiasis Consortium for Operational Research and Evaluation Intervention Studies
por: King, Charles H., et al.
Publicado: (2020) -
Persistent Hotspots in Schistosomiasis Consortium for Operational Research and Evaluation Studies for Gaining and Sustaining Control of Schistosomiasis after Four Years of Mass Drug Administration of Praziquantel
por: Kittur, Nupur, et al.
Publicado: (2019) -
Defining Persistent Hotspots: Areas That Fail to Decrease Meaningfully in Prevalence after Multiple Years of Mass Drug Administration with Praziquantel for Control of Schistosomiasis
por: Kittur, Nupur, et al.
Publicado: (2017)